NovaBay Pharmaceuticals CEO, Dr. Ron Najafi, Joins Distinguished Leaders Selected For This Year’s PharmaVOICE 100 Most Influential Leaders

By July 31, 2008

Ron Najafi, PhD, Chief Executive Officer and Chairman of Emeryville, CA-based NovaBay Pharmaceuticals (AMEX & TSX: NBY, https://novabay.com/), a clinical stage biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, was chosen as one of the “PharmaVOICE 100,” most influential leaders. “PharmaVOICE 100” is an annual list of individuals who are having a remarkable influence on the life sciences industry.

Dr. Najafi’s selection was based on his vision of developing and commercializing safe and effective non-antibiotic anti-infectives to reduce and replace usage of antibiotics in a number of non-systemic applications. He is seeking to change the paradigm of antibiotic usage. In an environment where many bacteria are becoming increasingly more resistant to antibiotics and are creating superinfections and unnecessary deaths, Dr. Najafi believes an alternative is imperative. “Dr. Najafi is impatient to reach his goal, so he impresses upon his team the need to find ways of moving things forward faster while being fully cognizant of the need to put safety first,” writes the editor of PharmaVOICE magazine. “If anyone has the will to make this goal a reality it is Dr. Najafi. A tenacious leader, ‘no’ means ‘not now’; he just doesn’t give up easily. His can-do attitude and belief that success is based on not giving up are contagious,” continued the editor.

Dr. Najafi and his team have discovered and are developing a class of non-antibiotic anti-infective compounds to treat a wide-range of infections, which they have named Aganocide® compounds. These compounds are based on the naturally occurring small molecules generated by neutrophils (white blood cells). According to PharmaVOICE, if all goes according to plan, the products NovaBay brings to market will have a significant impact in the fight against antibiotic resistant infections including MRSA.

“Being recognized by my peers and PharmaVOICE as someone who is inspiring others and contributing to the overall improvement and advancement of our industry is a great honor,” commented Dr. Najafi. “I am most excited about this recognition of the success we have had at NovaBay, and it is a direct reflection on the outstanding group of people we have that are dedicated to providing a solution to the growing problem of antibiotic resistance.”

This year’s distinguished list of one hundred leaders was selected by PharmaVOICE’s readers who nominated individuals in the industry that had inspired them; thousands of readers submitted nominations. Ultimately, the PharmaVOICE 100 was selected based on the number of nominations received and other factors, such as community and philanthropic activities.

PharmaVOICE divided the honorees into different categories that best capture their individual skill sets and expertise. Dr. Najafi was appropriately positioned in the “Leaders” category. As defined by PharmaVOICE, these entrepreneurs are redefining the life-sciences industry through innovative approaches to improving technologies, processes, services, and ultimately patient care.

The PharmaVOICE article can be seen on www.pharmavoice.com/100
or you can request a copy of the article by e-mailing Janet Vasquez at jvasquez@investorrelationsgroup.com.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.

NovaBay(TM), Aganocide(R), AgaNase(TM), and NeutroPhase(TM) are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Contact

Investor Relations:
The Investor Relations Group
Adam Holdsworth / Erica Ruderman
212-825-3210

Or

Media Relations:
Janet Vasquez / Laura Colontrelle
212-825-3210

TOP